Phase II study of carboplatin and pemetrexed plus bevacizumab after failure of first-line EGFR TKI therapy for non-small-cell lung cancer harboring EGFR mutation.
Phase 2
- Conditions
- on-squamous Non-small-cell Lung Cancer
- Registration Number
- JPRN-UMIN000004731
- Lead Sponsor
- Central Japan Lung Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
Not provided
Exclusion Criteria
1)Symptomatic brain metastasis 2)Hemoptysis (>=2.5ml) 3)Tumor invasion to the large blood vessel 4)Uncontrolled hypertension 5)Active infection 6)Severe underlying disease such as uncontrolled heart disease or diabetes mellitus 7)Receiving anticoagulants 8)Other concurrent active malignancy 9)Superior vena cava syndrome 10)Massive pleural or pericardial effusion, or ascites 11)Vertebral metastases requiring radiation therapy 12)Severe drug allergy 13)Active GI bleeding or inflammation in the abdominal cavity 14)Major surgery within 4 weeks 15)Pregnant or breast-feeding woman
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Progression free survival Overall survival Disease control rate 1 year survival rate Adverse events